The Massachusetts-based biotech company led by CEO Stéphane Bancel went from relative obscurity to the Wall Street spotlight when its mRNA-based COVID-19 vaccine, developed with scientists from the U.S. National Institute of Allergy and Infectious Diseases, became the first in the U.S. to start human testing last March. The vaccine’s December 2020 greenlight by the U.S. Food and Drug Administration—and its subsequent worldwide distribution—vindicates the company’s focus on using mRNA genetic material to teach the human body to fight off COVID-19. Millions have received the shot, and Moderna is ramping up production to meet continued worldwide demand.
More Must-Reads From TIME
- The 100 Most Influential People of 2024
- The Revolution of Yulia Navalnaya
- 6 Compliments That Land Every Time
- What's the Deal With the Bitcoin Halving?
- If You're Dating Right Now, You're Brave: Column
- The AI That Could Heal a Divided Internet
- Fallout Is a Brilliant Model for the Future of Video Game Adaptations
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time